Compare Endeavour Silver Corp (EXK) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs ResMed Inc. — how do they compare? Endeavour Silver Corp trades at $10.6 (market cap $3.14B), while ResMed Inc. trades at $225.01 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 10.4× Endeavour Silver Corp's market cap, and ResMed Inc. pays a 1.17% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals.
| EXK | RMD | |
|---|---|---|
Market Cap | $3.14B | $32.61B |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $293.73 |
52-Week Low | $5.31 | $182.82 |
Enterprise Value | $3.14B | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $10.68, up 4.3% today, with a bullish technical outlook driven by moving averages and strong analyst sentiment. The company reported Q2 2026 earnings in line with estimates at $0.15 per share, with revenue growth and operational execution highlighted in recent news. Financials show improving trends, with 2026 revenue projected at $737 million and net income turning positive to $66 million, though 2025 saw a net loss of $119 million. A new $25 million credit facility was secured in August 2026, supporting liquidity.
The stock offers upside to the consensus price target of $15.50, with 79% of analysts rating it Buy. Key risks include volatile silver prices, execution challenges at new mines, and high valuation multiples like a P/E of 52.95. Positive catalysts include production ramp-ups and favorable metal price outlooks, but investors should monitor debt levels and commodity cycles.
ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.
The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
